Study identifier:D1690C00012
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 24-week,Multi-centre,Int.,Double-blind,Rand.,Parallel-group,Plac.-controlled,Phase III Study with a 78-week Ext.Per. to Evaluate the Effect of Dapagliflozin in Combination with Metformin on Body Weight in Subjects with Type2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone
Type 2 Diabetes Mellitus
Phase 3
No
Dapagliflozin, Metformin, Sitagliptin, Placebo
All
182
Interventional
30 Years - 75 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Aug 2013 by AstraZeneca
AstraZeneca
Bristol-Myers Squibb
This study is being carried out to see if dapagliflozin in addition to metformin decreases body weight and if so, how it compares with metformin alone.
Location
Location
BLAGOEVGRAD, Bulgaria
Location
SOFIA, Bulgaria
Location
BEROUN, Czech Republic
Location
BRNO, Czech Republic
Location
PRAHA, Czech Republic
Location
SEMILY, Czech Republic
Location
SLANY, Czech Republic
Location
BALATONFURED, Hungary
Arms | Assigned Interventions |
---|---|
Experimental: A Dapagliflozin 10 mg plus Metformin | Drug: Dapagliflozin Tablet oral 10 mg total daily dose once daily 102 weeks Drug: Metformin Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks Drug: Sitagliptin Tablet oral 100 mg total daily dose once daily rescue medication |
Placebo Comparator: B Placebo plus Metformin | Drug: Metformin Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks Drug: Sitagliptin Tablet oral 100 mg total daily dose once daily rescue medication Drug: Placebo Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.